期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
N2 disease in non-small cell lung cancer patients,diagnosis and evaluation:a Turkish chest surgeon s perspective 被引量:2
1
作者 Alper TOKER 《中国肺癌杂志》 CAS 2008年第5期622-626,共5页
Mediastinal or N2 disease is the most important factor in selecting the optimal treatment strategy in patients without distant metastasis.A direct surgical resection has not generally been accepted as a treatment moda... Mediastinal or N2 disease is the most important factor in selecting the optimal treatment strategy in patients without distant metastasis.A direct surgical resection has not generally been accepted as a treatment modality in whom mediastinal nodal involvement is demonstrated.Patients with lung cancer can be diagnosed as clinical N2 disease based on CT and PET-CT characteristics of the mediastinum and the clinical presentation.Invasive diagnostic modalities used in the detection of N2 disease are:mediastinoscopy,endoesophageal ultrasound guided biopsy(EUS),transbronchial needle aspiration(TBNA),endobronchial ultrasound guided biopsy(EBUS),video-assisted thoracoscopic surgery(VATS),and mediastinotomy/extended mediastinoscopy.In this article,the author discusses about invasive and noninvasive techniques on the evaluation of mediastinal disease and presents his experience on this topic. 展开更多
关键词 mediastinum Neoplasm staging Lung neoplasms
下载PDF
Assessment of multimodality therapy for thymoma
2
作者 CHEN Jie WANG Ping 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第10期1295-1298,共4页
Background This study was designed to analyze the accuracy and reliability of several prognostic indicators for long-term survival of thymoma patients. Methods Data from 142 patients treated for thymoma at the Tianjin... Background This study was designed to analyze the accuracy and reliability of several prognostic indicators for long-term survival of thymoma patients. Methods Data from 142 patients treated for thymoma at the Tianjin Medical University Cancer Hospital from January 1954 to January 2001 were retrospectively analyzed. The Kaplan-Meier method and Cox's proportional hazards model test were used for single and multi-variable analyses respectively. The Log-rank test was used to compare survival between groups. Results The sizes and extent of the tumors were classified as I-IV according to the Masaoka clinical staging scale. Respective 5- and 10-year survival rates were: 93.8% and 79.2% in stage I, 79.3% and 55.2% in stage II, 53.1% and 34.4% in stage III, and no survivors in stage IV. Among 30 patients with associated myasthenia gravis, 19 had generalized myasthenia gravis and 11 had ocular myasthenia gravis; 5- and 10-year survival rates were 83.3% and 60.0%, respectively. The 5- and 10-year survival rates for 112 patients without myasthenia gravis were 53.6% and 42.0%, respectively. Eighty-four patients had radical resection and nine had palliative resection. Eighty-nine patients had radiotherapy and 55 patients had postoperative radiotherapy. Single or multi-variable analyses showed that the main prognostic indicators are Masaoka clinical staging, thymoma-associated myasthenia gravis, and the treatment method. Conclusions The most important indicators of long-term survival in thymoma are Masaoka clinical staging and the completeness of resection. The primary treatment method for thymoma should be wide tumor resection. Pre- and/or postoperative radio- and/or chemotherapy should be given according to individual treatment requirements. 展开更多
关键词 thymus neoplasms mediastinum neoplasms RADIOTHERAPY PROGNOSIS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部